1. Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, Carmiel M, Chodick G, Conway B, Song Y, Gasbarrini A, Hüppe D, Plaza FJ, Lampertico P, Alonso MLM, Myles L, Persico M, Ramji A, Sarrazin C, Villa E, Weil C, Otano JIU; CREST Study Group. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. Adv Ther. 2022 Jul;39(7):3146-3158. 

2. Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. J Viral Hepat. 2018 Feb;25(2):144-151.

3. Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization. J Med Virol. 2016 Jun;88(6):1044-50.

4. Weil C, Nwankwo C, Friedman M, Shalev V, Chodick G. Real-World Data on Multiple Comorbidities Among Patients With Hepatitis C: Considerations for Patient Care And Prognosis. VOLUME 18, ISSUE 7, PA543, NOVEMBER 01, 2015. Value Health/ISPOR - Open Archive DOI:https://doi.org/10.1016/j.jval.2015.09.1723.

1. Yanover C, Mizrahi B, Kalkstein N, et al. What Factors Increase the Risk of Complications in SARS-CoV-2-Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization. JMIR Public Health Surveill. 2020;6(3):e20872. 

1. Sharman Moser S, Chodick G, Gelerstein S, Barit Ben David N, Shalev V, Stein-Reisner O. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. BMC Psychiatry. 2022 Aug 11;22(1):541.

2. Jennifer Kertes, MPH (research conducted as part of PhD), Orit Stein Reisner, MD, MBA, Leon Grunhaus, MD, Ronit Nezry, MPH, Tamar Alcalay, MPH, Joseph Azuri, MD, MHA, Yehuda Neumark, PhD, MPH, Comparison of Smoking Cessation Program Registration, Participation, Smoking Cessation Medication Utilization, and Abstinence Rates Between Smokers With and Without Schizophrenia, Schizo-affective Disorder, or Bipolar Disorder, Nicotine & Tobacco Research, 2021; ntab202 (https://doi.org/10.1093/ntr/ntab202)

3. Jennifer Kertes, Yehuda Neumark, Leon Grunhaus & Orit Stein-Reisner (2021) Comparison of Perceptions and Smoking Cessation Experiences Between Smokers With and Without Serious Mental Illness in a Large Health Maintenance Organization, Journal of Dual Diagnosis, 17:4, 284-295.

4. Jennifer Kertes, Orit Stein Reisner, Leon Grunhaus & Yehuda Neumark (2021) The Impact of Smoking Cessation on Hospitalization and Psychiatric Medication Utilization among People with Serious Mental Illness, Substance Use & Misuse, 56:10, 1543-1550.

5. Ben Zaken S, Radomysky Z, Koren G. Association Between Serum Magnesium Levels and Alzheimer's Disease or Mixed Dementia Patients: A Population-Based Retrospective Controlled Study. J Alzheimers Dis Rep. 2020 Sep 28;4(1):399-404. 

6. Yanover C, Mizrahi B, Kalkstein N, Marcus K, Akiva P, Barer Y, Shalev V, Chodick G. What Factors Increase the Risk of Complications in SARS-CoV-2-Infected Patients? A Cohort Study in a Nationwide Israeli Health Organization. JMIR Public Health Surveill. 2020 Aug 25;6(3):e20872.

7. Kodesh A, Goldshtein I, Gelkopf M, Goren I, Chodick G, Shalev V. Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization. Soc Psychiatry Psychiatr Epidemiol. 2012 Nov;47(11):1775-82.

1. Meaddough EL, Sarasua SM, Fasolino TK, Farrell CL. The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review. The Pharmacogenomics Journal. 2021 Aug;21(4):409-22.

2. Petrilla AA, Shah A, Feliciano J, Woolery J, LeBlanc TW. Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting. Current medical research and opinion. 2021 Jul 3;37(7):1189-97.

3. Madduri D, Hagiwara M, Parikh K, Pelletier C, Delea TE, Kee A, Chari A. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncology. 2021 Feb;17(5):503-15.

4. Pollissard L, Shah A, Punekar RS, Petrilla A, Pham HP. Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura. Journal of Medical Economics. 2021 Jan 1;24(1):706-16.

5. Mentz RJ, Pulungan Z, Kim S, Yang M, Teigland C, Hilkert R, Djatche LM. Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. Journal of medical economics. 2021 Jan 1;24(1):698-705.

6. Shah A, Petrilla A, Rebeira M, Feliciano J, Lisano J, LeBlanc TW. Health care resource utilization and costs among Medicare beneficiaries newly diagnosed with peripheral T-cell lymphoma: a retrospective claims analysis. Clinical Lymphoma Myeloma and Leukemia. 2021 Jan 1;21(1):e1-9.

7. Pollissard L, Shah A, Punekar R, Petrilla A, Pham HP. Burden of Illness Among Medicare and Non-Medicare Populations with Acquired Thrombotic Thrombocytopenic Purpura, 2010-2018. Blood. 2020 Nov 5;136:19-20.

8. Petrilla AA, Sutton BS, Leinwand BI, Parente A, Ferrari L, Wade CT. Incremental burden of mental health conditions in adult patients with focal seizures. Epilepsy & Behavior. 2020 Nov 1;112:107426.

9. Petrilla A, Marrett E, Shen X, Kwong WJ, Pezalla E. Association between formulary coverage and use of abuse-deterrent prescription opioids, risk for abuse or overdose, and associated healthcare resource utilization. American health & drug benefits. 2020 Feb;13(1):21.

10. Forma F, Green T, Kim S, Teigland C. Antipsychotic medication adherence and healthcare services utilization in two cohorts of patients with serious mental illness. ClinicoEconomics and Outcomes Research: CEOR. 2020;12:123.